Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
J&J negotiates to buy Actelion
by Ann M. Thayer
December 5, 2016
| A version of this story appeared in
Volume 94, Issue 48
Johnson & Johnson and Switzerland’s Actelion Pharmaceuticals confirm that they have held preliminary discussions about a potential transaction. According to news reports, J&J has made two bids well above Actelion’s current market value of about $21 billion. The nearly 20-year-old Swiss firm is recognized for its development of endothelin receptor antagonists, which include the pulmonary arterial hypertension drug Tracleer and newer potential PAH blockbusters Opsumit and Uptravi. For the first nine months of 2016, Actelion had sales of $1.75 billion.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X